IRAK4 and rheumatoid arthritis: An orally bioavailable heterobifunctional IRAK4 degrader (KT-474) in phase I clinical trials (NCT04772885) could treat patients with various immuno-inflammatory diseases, such as rheumatoid arthritis, atopic dermatitis or hidradenitis suppurativa.